Blood brain barrier

World Parkinson's Day
#AskBio #Blood brain barrier #FDA #Gene therapy #Parkinson's #Regulatory

How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease

Bruno Quinney speaks to Adrian Kells, Senior Vice President and Integrated Product Team Lead PD at AskBio, about the company’s gene therapy programme and pioneering treatment for Parkinson’s. The drug discovery landscape for Parkinson’s disease is becoming one of the most exciting frontiers in the industry. It is unsurprising to… Read More

#Exclusive Content

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  A leading news story this week has been the announcement of positive Phase II… Read More

#News

#Blood brain barrier #Calliditas Therapeutics #Cancer #Cancer research #Clinical trials #Drug discovery #Head and neck cancer #Immunotherapy #Neuroscience #Oncology #Plant-based #Schizophrenia #Smoking cessation #Squamous cell carcinoma #Vaping

This week in drug discovery (6-10 May) 

News round-up for 6-10 May by DDW Multimedia Editor Megan Thomas. A leading news story this week has been the announcement of positive Phase II results of a head and neck cancer trial, but there have been a number of other interesting clinical result announcements. These include the… Read More

#News

#Blood brain barrier #Drug discovery #Neuroscience

Nutrient research reveals pathway for treating brain disorders 

Dr Rosemary Cater, a University of Queensland (UQ) researcher, has found molecular doorways that could be used to help deliver drugs into the brain to treat neurological disorders. Dr Carter from UQ’s Institute for Molecular Bioscience led a team which discovered that an essential nutrient called choline is transported into the… Read More

#News

Brain inflammation
#Amyotrophic lateral sclerosis (ALS) #Axoltis Pharma #Blood brain barrier #Clinical trials #Neuroscience #Regulatory

Drug candidate for ALS patients authorised for Phase II trial

Axoltis Pharma has received authorisation from ANSM, the French agency for the safety of health products, to launch the SEALS study for Amyotrophic Lateral Sclerosis (ALS).   This Phase II clinical trial of drug candidate NX210c in patients with ALS is the first to target the integrity of the blood brain… Read More

#News #Regulatory